Adaptive resistance to targeted therapies in cancer

Translational Lung Cancer Research

Volumn 2, Issue 3, 2013, Pages 152-159

  Rosell, Rafael ^a,b   Karachaliou, Niki ^b   Morales Espinosa, Daniela ^c   Costa, Carlota ^b   Molina, Miguel Angel ^b   Sansano, Irene ^b,d   Gasco, Amaya ^b   Viteri, Santiago ^b   Massuti, Bartomeu ^e   Wei, Jia ^f   Cao, María González ^b   Bueno, Alejandro Martínez ^b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

^c LIVER RESEARCH UNIT   (Mexico)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^f THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

Author keywords

Adaptive resistance; RTK reprogramming; Signalability; Synthetic lethality

Indexed keywords

EID: 84891832586     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2012.12.08     Document Type: Review

References (29)

1. Duncan JS, Whittle MC, Nakamura K, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012;149:307-21.
2. Lito P, Pratilas CA, Joseph EW, et al. Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas. Cancer Cell 2012;22:668-82.
3. Chandarlapaty S, Sawai A, Scaltriti M, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011;19:58-71.
4. Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov 2011;1:248-59.
5. Zhang Z, Lee JC, Lin L, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012;44:852-60.
6. Straussman R, Morikawa T, Shee K, et al. Tumour microenvironment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012;487:500-4.
7. Wilson TR, Fridlyand J, Yan Y, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012;487:505-9.
8. Corcoran RB, Ebi H, Turke AB, et al. EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012;2:227-35.
9. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012;483:100-3.
10. Maraver A, Fernandez-Marcos PJ, Herranz D, et al. Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. Cancer Cell 2012;22:222-34.
11. Red Brewer M, Choi SH, Alvarado D, et al. The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell 2009;34:641-51.
12. Turke AB, Song Y, Costa C, et al. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res 2012;72:3228-37.
13. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118:3065-74.
14. Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008;27:5527-41.
15. Johnson BE, Jackman D, Jänne PA. Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer. Clin Cancer Res 2007;13:s4628-31.
16. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8.
17. Vo DT, Abdelmohsen K, Martindale JL, et al. The oncogenic RNA-binding protein Musashi1 is regulated by HuR via mRNA translation and stability in glioblastoma cells. Mol Cancer Res 2012;10:143-55.
18. Alain T, Morita M, Fonseca BD, et al. eIF4E/4E-BP Ratio Predicts the Efficacy of mTOR Targeted Therapies. Cancer Res 2012;72:6468-76.
19. Acquaviva J, Smith DL, Sang J, et al. Targeting KRASMutant Non-Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib. Mol Cancer Ther 2012;11:2633-43.
20. Spoerke JM, O'Brien C, Huw L, et al. Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models. Clin Cancer Res 2012;18:6771-83.
21. Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 2008;321:1499-502.
22. Scott KL, Kabbarah O, Liang MC, et al. GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature 2009;459:1085-90.
23. Britschgi A, Andraos R, Brinkhaus H, et al. JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer. Cancer Cell 2012;22:796-811.
24. Morgillo F, Woo JK, Kim ES, et al. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006;66:10100-11.
25. Zheng H, Shen H, Oprea I, et al. ß-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma. Proc Natl Acad Sci U S A 2012;109:20620-5.
26. Kovacs JJ, Hara MR, Davenport CL, et al. Arrestin development: emerging roles for beta-arrestins in developmental signaling pathways. Dev Cell 2009;17:443-58.
27. Wolf I, Levanon-Cohen S, Bose S, et al. Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene 2008;27:7094-105.
28. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42.
29. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.